Patient P-02300
Synthetic patientMETA-24 · Day 107 · 65–74 · F · baseline S06Steering view · 3DOpen companion preview
Therapy response
Improving
Tolerance
Favorable
GI state
Deteriorating
Inflammatory state
Improving
Nutritional resilience
Declining
Discontinuation risk
14%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S06
What changed?
Trajectory is tracking the baseline prediction.
Primary contributors, last 14 days
- Treatment adherence+10
- GI instability+6
- Inflammatory activity-6
- Nutritional resilience-4
What helped?
No interventions yet.
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Active minutes
Wearable35 min
stable · -0.4 vs previous 14 d
Sleep duration
Wearable7.4 h
stable · -0.2 vs previous 14 d
Energy level
Daily log7.1/10
stable · -0.2 vs previous 14 d
Steps
Wearable4,333
stable · -32 vs previous 14 d
GI burden
Companion16.5/100
worsening · +8.4 vs previous 14 d
Adherence
Companion100 %
stable · +0.6 vs previous 14 d
Sleep quality
Wearable53.6/100
worsening · -6.0 vs previous 14 d
Glucose, CGM daily mean
CGM129 mg/dL
stable · +4.8 vs previous 14 d
This trajectory is doing well — what to keep, what to watch
Steering view →Heading towards restoration · 93 from the failing basin, 7 from restoration.
Good elements to keep
- Butyrate producers intacthidden · steering +7.5
- Protein (supports)perturbation · steering +7
- Proteinsupporter · GI -4.1 next day
Main detractors to watch
- Rapid metabolizerhidden · steering -8
- Bacteroides fragilis elevatedhidden · steering -7.4
- Alcoholperturbation · steering -5.6
- Antibiotic courseperturbation · steering -4.7
- Alcoholdetractor · GI +3.2 next day
- Histamine loaddetractor · GI +2.7 next day
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Protein-4.1supporter · 95%
- Alcohol+3.2detractor · 83%
- Histamine load+2.7detractor · 70%
- Caffeine-1.2no signal · 31%
- Insoluble fibre+0.5no signal · 15%
- Dietary fat load-0.3no signal · 15%
- Simple carbohydrates-0.2no signal · 15%
- Ultra-processed food-0.1no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓25
- MicrobiomeF. prausnitzii depleted
- Inflammatory signalling ↓20
- MicrobiomeBacteroides fragilis expansion
DNA
Fictional pharmacogenomic panel
- CYP2D6 Rapid metabolizerExpected exposure
Microbiome
Shannon diversity 4.4 · butyrate capacity 56/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 49 ms
- Sleep
- 7.5 h
- Steps
- 4,753
- Resting HR
- 73 bpm
Daily log: GI score 17, nutritional resilience 64, adherence 100.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Log the daily check-in; one line is enough
- A 15-minute walk after lunch
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02555 | 55% | S01 | AD-05 | no change | 79 |
| P-02277 | 45% | S05 | AD-05 | improved | 92 |
| P-02282 | 45% | S01 | BR-03 | no change | 88 |
| P-02013 | 41% | S14 | BR-03 | no change | 94 |
| P-02193 | 40% | S11 | CR-01 | improved | 87 |
| P-02354 | 33% | S01 | CR-01 | improved | 78 |
| P-02081 | 49% | S20 | DT-01 | no change | 88 |
| P-02565 | 46% | S09 | DT-01 | no change | 79 |
| P-02249 | 39% | S09 | DT-01 | improved | 100 |
| P-02337 | 37% | S18 | DT-01 | no change | 100 |
| P-02462 | 33% | S12 | DT-01 | improved | 65 |
| P-02518 | 32% | S17 | DT-01 | improved | 68 |